SCHEMBL21150756

SCHEMBL21150756

CC(C)(C)OC(=O)CCS(=O)(=O)N1CCC(N2CC(=O)N(c3ccccc3)C2=O)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.37
KMT2A Q03164 4/20 0.36
KDM4E B2RXH2 1/20 0.35
F2 P00734 1/20 0.35
F10 P00742 1/20 0.35
PRSS1 P07477 1/20 0.35
CCKAR P32238 1/20 0.35
MEN1 O00255 2/20 0.35
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
HPGD P15428 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HSD17B10 Q99714 1/20 0.34
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34
LMNA P02545 1/20 0.34
MT-CO2 P00403 1/20 0.34
ALOX5 P09917 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
RAMP1 O60894 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21150757 0.86 ALDH1A1 (0.39) KMT2AKDM4EF2F10PRSS1
SCHEMBL24974652 0.81 MT-CO2 (0.42) GPR119KMT2AMEN1ALDH1A1MAPT
SCHEMBL24974367 0.80 SMN1; SMN2 (0.40) KMT2AKDM4EMEN1
SCHEMBL21150798 0.79 GPR119 (0.57) GPR119KDM4EMAPTTP53
SCHEMBL21150772 0.74 ITGB3 (0.38) GPR119MAPTNPC1LMNA
SCHEMBL24974603 0.71 NAMPT (0.43) KMT2AKDM4EMEN1ALDH1A1MAPT
SCHEMBL21150805 0.69 YAP1 (0.46) KMT2AKDM4EF2F10MEN1
SCHEMBL21150753 0.67 GRM4 (0.46) KMT2AMEN1ALDH1A1
SCHEMBL24974751 0.67 ALDH1A1 (0.38) KMT2AKDM4EF2F10PRSS1
SCHEMBL29590229 0.67 GRM4 (0.48) KMT2AMEN1ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 US disclosed
WO-2019136442-A1 CD16A BINDING AGENTS AND USES THEREOF KLEO PHARMACEUTICALS, INC. (US) 2019-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B GPR119 926/4885KMT2A 499/4885KDM4E 2126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.